B of A Securities Maintains Buy on Kymera Therapeutics, Raises Price Target to $144

Benzinga Newsdesk www.benzinga.com Positive 87.3%

Neg 0% Neu 0% Pos 87.3%

B of A Securities analyst Tazeen Ahmad maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $123 to $144.